A Phase II Study of Metronomic Daily Oral Vinorelbine as First-Line Chemotherapy in Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Resistant to Endocrine Therapy: Vinometro
Title:
A Phase II Study of Metronomic Daily Oral Vinorelbine as First-Line Chemotherapy in Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer Resistant to Endocrine Therapy: Vinometro
Author:
Thomssen, Christoph Decker, Thomas Fehm, Tanja Fuxius, Stefan Harbeck, Nadia Juhasz-Böss, Ingolf Möbus, Volker Seehase, Martina Schollenberger, Lukas Ruckes, Christian Schmidt, Marcus